Physiologic Performance Response to Salbutamol

Not Applicable

• Conditions: Healthy
• Interventions: Drug: salbutamol; Drug: Placebo

• Registration Number: NCT04615611
• Lead Sponsor: University of Copenhagen

Brief Summary

This project aims to investigate the individual physiological response to beta2-adrenergic stimulation with salbutamol on performance-related outcomes

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-10
• Study First Submitted: 2020-10-29
• Study First Submitted QC: 2020-10-29
• Last Update Submitted: 2020-10-29
• Study First Posted: 2020-11-04
• Last Update Posted: 2020-11-04
• Study Start: 2020-11-07
• Primary Completion: 2021-11-07
• Study Completion: 2021-11-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• 18 to 45 years of age
• Trained individuals with maximal oxygen uptake above 55 mL/kg/min for men and 50 mL/kg/min for women
• Body mass index lower than 26

Exclusion Criteria

• Allergy towards study drug
• Unacceptable side effects of the study drug
• Chronic disease deemed by the MD to impose a risk or severely confound the study outcomes
• Current smokers
• Use of prescription medicine
• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
salbutamol	salbutamol	salbutamol, 800 microgram from metered dose inhaler
placebo	Placebo	placebo

Primary Outcome Measures

Name	Time	Method
Sprint performance	Measured ½ hour after drug administration	Power output during maximal cycling

Secondary Outcome Measures

Name	Time	Method
Cycling endurance performance	Measured ½ hour after drug administration	4-min time trial on bike ergometer
Muscle strength	Measured ½ hour after drug administration	Quadriceps maximal voluntary contraction
Sprint fatigue tolerance	Measured ½ hour after drug administration	Fatigue index during maximal cycling